# A Phase 1/2 Study of SHP648, an Adeno-Associated Viral Vector for Gene Transfer in Hemophilia B Subjects

> **NCT04394286** · PHASE1,PHASE2 · TERMINATED · sponsor: **Baxalta now part of Shire** · enrollment: 2 (actual)

## Conditions studied

- Hemophilia B

## Interventions

- **GENETIC:** SHP648

## Key facts

- **NCT ID:** NCT04394286
- **Lead sponsor:** Baxalta now part of Shire
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-05-13
- **Primary completion:** 2021-05-03
- **Final completion:** 2021-05-03
- **Target enrollment:** 2 (ACTUAL)
- **Why stopped:** Takeda has decided to not further develop the SHP648 (TAK-748) program. No subjects have been dosed with SHP648. The decision to terminate study SHP648-101 is not due to any safety concerns.
- **Last updated:** 2022-05-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04394286

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04394286, "A Phase 1/2 Study of SHP648, an Adeno-Associated Viral Vector for Gene Transfer in Hemophilia B Subjects". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04394286. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*